
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is a promising company with a strong financial performance, unique product offerings, and growth potential in new markets. The company's strong cash flow, share repurchase plans, and efforts towards expanding into primary care and the closed-loop system market for Type 2 diabetes are key factors in their success. Ongoing cost reduction and improved gross margins will play a critical role in maintaining their success in the long-term.
Bears say
Insulet is facing increased R&D investments for the development of its Omnipod 6 and closed loop system for T2 diabetic patients, which will not be launched until FY27 and FY28, respectively. This, along with a reduction in the price target by analysts, suggest potential hindered growth and profitability for the company. In addition, the company's current price to sales multiple is significantly higher than the aggregate MedTech space, indicating a potential overvaluation of the stock.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares